Unsubscribe

A message from Brownstone Research

Editor’s Note: What if you could claim a stake in what’s set to be the biggest IPO ever… starting with just $500? Click here to see the details from former tech executive and angel investor Jeff Brown — the man who picked Bitcoin, Tesla, and Nvidia before they exploded higher. Or read more below.

---

Dear Reader,

Elon Musk just unlocked the biggest investment opportunity of the year.

He’s about to take SpaceX public in what’s set to be the biggest IPO ever.

The New York Times predicted it “will unleash gushers of cash for Silicon Valley and Wall Street.”

If you click here and learn what to do…

Some of that cash could end up in your pocket.

ATTENTION: There’s no need to wait for the company to go public.

You can claim your stake today.

But hurry… 

Elon Musk has already interviewed the Wall Street banks that will file all the paperwork and take the company public.

And he has already announced his IPO plans to his shareholders…

Confirming that it will happen soon… 

I believe he’ll file the paperwork by the end of this month…

That’s why I’m urging you to click here and learn how to claim your stake now.

Look, this might be the most anticipated IPO in the history of mankind.

Once the company goes public, for the first time ever…

Hundreds of millions of investors around the world…

Will have a chance to buy shares of one of Elon’s most successful companies.

I believe it’s going to be a stampede like we’ve never seen before.

But you can get ahead of the crowd.

Just click here and I’ll show you how to get started. 

We have so much to look forward to,

Jeff Brown
Founder & CEO, Brownstone Research

---

More Reading from MarketBeat.com

When Insider Selling Is a Good Thing: 2 Stocks to Watch

Written by Thomas Hughes. Article Published: 3/23/2026. 

Key Points

• Waste Management insiders sold roughly $25 million in stock after shares hit an all-time high in early 2026, but institutional accumulation and a growing dividend keep the long-term outlook bullish.
• Ionis Pharmaceuticals faces heavier insider and institutional selling, though analysts see roughly 25% upside driven by the commercial ramp of Olezarsen.
• Both stocks have pulled back from recent highs, potentially creating entry points for investors willing to look past short-term selling pressure.
• Special Report: Musk and Bezos are racing to blanket the planet – here’s why (From True Market Insiders)

Insider selling can be constructive when corporate insiders are simply taking profits in stocks whose outlooks are getting more bullish. In this piece, one name is a steady, cash-generating dividend-growth machine, while the other is a commercial-stage biopharma with an outlook for double-digit — approaching hyper — growth. In both cases, recent insider sales helped trigger pullbacks from early-2026 highs, creating potential entry points for new investors.

Waste Management Doesn’t Waste Time: Growth and Dividends in 2026

Waste Management (NYSE: WM) rallied about 25% from its 2025 low to a new all-time high in early 2026. Those highs prompted insiders — including the CEO, CFO, CAO, COO and several VPs — to sell shares. That selling helped cap gains in Q1 but is otherwise immaterial to the longer-term outlook: insiders own only 0.18% of shares outstanding, and sales totaled less than $25 million.

Have $500? Invest in Elon’s AI Masterplan (Ad)

What if you could claim a stake in what’s set to be the biggest IPO ever… starting with just $500?

Everyone is talking about Elon Musk’s SpaceX IPO.Click here to get the details and I’ll show you how to claim your stake…

Institutional activity shows accumulationover the trailing 12 months, with activity ramping in 2025 and remaining strong into 2026. Institutions own roughly 80% of the company, and this group has been accumulating for about three years without distribution quarters — a trend the earnings and capital-return outlook suggests could continue.

Analysts are also constructive, with 25 tracked ratings for 2026. That coverage provides both support and a price tailwind, as analyst coverage has increased on a trailing-twelve-month basis.

Sentiment is firming: the consensus rating sits at Moderate Buy and is approaching Strong Buy, while price targets are trending higher. The late-March consensus implies roughly 10% upside, which would be enough to reach a new all-time high if the analyst outlook plays out.

The dividend is another reason to consider the stock. Waste Management yields about 1.65% in early 2026, the payout ratio is sustainable at roughly 56% of earnings, and the company has a history of annual increases. Management appears on track for potential inclusion in the S&P Dividend Aristocrats Index by the end of the decade — an outcome that typically increases buy-and-hold ownership, reduces volatility, and supports a longer-term uptrend.

Ionis Pharmaceuticals: A Cautious Outlook for a Potential Blockbuster

Ionis Pharmaceuticals (NASDAQ: IONS)is an RNA-focused biopharma with multiple marketed products and two drivers that matter most. Spinraza — marketed through a partnership — still generates large sales but is in decline. The other is Olezarsen, a wholly owned candidate expected to reach peak sales north of $2 billion; many analysts view that $2 billion estimate as conservative, and price targets have been rising accordingly.

Insider selling at Ionis mirrors the pattern at Waste Management in early 2026, but with important differences. Ionis insiders also sold heavily in 2025, and institutional investors have been pulling back as well. Institutions own more than 90% of the stock, and their profit-taking in 2025 and into Q1 2026 represents a meaningful headwind.

Analysts provide the offset. Institutions have taken profits after the stock more than doubled from its 2025 low, but analyst coverage — 21 tracked analysts — yields a consensus Moderate Buy. Coverage is expanding, sentiment is firming, and price targets are trending upward; the consensus implies about 25% upside by year-end, while the high end of analyst targets adds about another 10% on top of that.

The growth story is the reason to own Ionis. The company is forecast to sustain a high-20% growth rate well into the next decade, reach profitability in 2028, and steadily improve thereafter. On long-term forecasts, a valuation at roughly 7x projected 2035 earnings would still leave substantial upside — the stock could more than double under that scenario and still appear inexpensive. If Olezarsen meets or exceeds conservative peak-sales estimates and the pipeline delivers additional commercial successes, the upside could be materially higher.

Thank you for subscribing to StockReport.com, our daily newsletter that highlights a new stock each day.

This email content is a sponsored message sent on behalf of Brownstone Research, a third-party advertiser of StockReport.com and MarketBeat. 

If you need assistance with your newsletter, please contact us at contact@stockreport.com.

If you no longer wish to receive email from StockReport.com, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC dba StockReport.com. 
345 N Reid Pl., Sixth Floor, Sioux Falls, S.D. 57103-7078. U.S.A..